Patent Suit Against Amgen Is Dismissed

Amgen Inc. won a court ruling that eliminates a patent challenge to its third-biggest drug, arthritis treatment Enbrel.

Israel Bio-Engineering Project accused Amgen and marketing partner Wyeth of infringing a U.S. patent it said covered Enbrel. A U.S. judge said Yeda Research and Development Co., which licenses inventions of the Weizmann Institute of Science in Israel, is the owner of the patent, not Israel Bio-Engineering, and dismissed the suit.